For NSCLC, the recently reported results for a clinical trial using the PI3K inhibitor buparlisib (a class I pan-PI3K inhibitor) showed that tumor responses were only found in 3% of SQCC and non-squamous NSCLC patients (selected to exhibit activation of PI3K pathway) [16, 17]. Here, PIK3CD is linked to neoplasm.